Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 7 recruiting clinical trials
Metastatic prostate cancer (≥1 prior LOT)
8343PCR1003
Phase
b
NCT05818683
Compound
Pasritamig (KLK2 × CD3 bispecific Ab) + cetrelimab (anti–PD-1 mAb), taxane chemotherapy or ARPIs
Metastatic CRPC
9401PCR1001
Phase
NCT06095089
Compound
JNJ-87189401 (PSMA × CD28 bispecific Ab) + pasritamig (KLK2 × CD3 bispecific Ab)
Metastatic CRPC
78278343PBPCR1004
Phase
b
NCT07082920
Compound
Pasritamig (KLK2 × CD3 bispecific Ab) + JNJ-95298177 (PSMA-targeting ADC)
Metastatic CRPC
KLK2-comPAS
Phase
NCT07164443
Compound
Pasritamig (KLK2 × CD3 bispecific Ab) + best supportive care
Metastatic CRPC
KLK2-PASenger
Phase
NCT07225946
Compound
Pasritamig (KLK2 × CD3 bispecific Ab) + docetaxel
Metastatic CRPC (≥1 prior LOT, including an ARPI)
HLD-0915-ONC-101
Phase
NCT06800313
Compound
JNJ-101556143*
Metastatic CRPC
78278343PBPCR1005
Phase
b
NCT07319871
Compound
Pasritamig (KLK2 × CD3 bispecific Ab) + JNJ-86974680 (adenosine 2a receptor antagonist)
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.
*Other name: HLD-0915
Ab, antibody; ADC, antibody-drug conjugate; ARPI, androgen receptor pathway inhibitor; CD, cluster of differentiation; CRPC, castration-resistant prostate cancer; KLK2, human kallikrein-2; LOT, line of therapy; mAb, monoclonal antibody; PD-1, programmed cell death protein-1; PSMA, prostate-specific membrane antigen.